APA (7th ed.) Citation

A, A., J, S., H, U., N, A., RA, J., K, B., . . . M, H. (2021). Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer. International journal of biological sciences, 17(15), 4474. https://doi.org/10.7150/ijbs.62236

Chicago Style (17th ed.) Citation

A, Ali, Shafarin J, Unnikannan H, Al-Jabi N, Jabal RA, Bajbouj K, Muhammad JS, and Hamad M. "Co-targeting BET Bromodomain BRD4 and RAC1 Suppresses Growth, Stemness and Tumorigenesis by Disrupting the C-MYC-G9a-FTH1axis and Downregulating HDAC1 in Molecular Subtypes of Breast Cancer." International Journal of Biological Sciences 17, no. 15 (2021): 4474. https://doi.org/10.7150/ijbs.62236.

MLA (9th ed.) Citation

A, Ali, et al. "Co-targeting BET Bromodomain BRD4 and RAC1 Suppresses Growth, Stemness and Tumorigenesis by Disrupting the C-MYC-G9a-FTH1axis and Downregulating HDAC1 in Molecular Subtypes of Breast Cancer." International Journal of Biological Sciences, vol. 17, no. 15, 2021, p. 4474, https://doi.org/10.7150/ijbs.62236.